Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207)

Human Gene Therapy

Volumn 10, Issue 10, 1999, Pages 1599-1606

  Carew, John F ^a   Kooby, David A ^a   Halterman, Marc W ^b   Federoff, Howard J ^b   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; HEAD AND NECK CANCER; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; INFECTION; MOUTH TUMOR; NONHUMAN; RAT; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 0033166680     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017608     Document Type: Article

References (13)

1. CHOU, J., KERN, E.R., WHITLEY, R.J., and ROIZMAN, B. (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture. Science 250, 1262-1266.
2. CLAYMAN, G.L., LIU, T.J., OVERHOLT, M., MOBLEY, S.R., WANG, M., JANOT, F., and GOEPFERT, H. (1996). Gene therapy for head and neck cancer: Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21). Arch. Otolaryngol. Head Neck Surg. 122, 489-493.
3. GELLER, A.I., BREAKEFIELD, X.O. (1988). A defective HSV-1 vector expresses Escherichia coli β-galactosidase in cultured peripheral neurons. Science 241, 1667-1669.
4. GOEBEL, E.A., DAVIDSON, B.L., GRAHAM, S.M., ZABNER, J., and KERN, J.A. (1996). Adenovirus-mediated gene therapy for head and neck squamous cell carcinomas. Ann. Otol. Rhinol. Laryngol. 105, 562-567.
5. KUCHARCZUK, J.C., RANDAZZO, B., CHANG, M.Y., AMIN, K.M., ELSHAMI, A.A., STERMAN, D.H., RIZK, N.P., MOLNARKIMBER, K.L., BROWN, S.M., MACLEAN, A.R., LITZKY, L.A., FRASER, N.W., ALBELDA, S.M., and KAISER, L.R. (1997). Use of a replication-restricted herpes virus to treat experimental human malignant mesothelioma. Cancer Res. 57, 466-471.
6. LIU, T.J., ZHANG, W.W., TAYLOR, D.L., ROTH, J.A., GOEPFERT, H., and CLAYMAN, G.L. (1994). Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res. 54, 3662-3667.
7. MINETA, T., RABKIN, S.D., YAZAKI, T., HUNTER, W.D., MARTUZA, R.L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. 1, 938-943.
8. MIYATAKE, S.I., MARTUZA, R.L., and RABKIN, S.D. (1997). Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther. 4, 222-228.
9. O'MALLEY, B.W., CHEN, S.H., SCHWARTZ, M.R., and WOO, S.L. (1995). Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res. 55, 1080-1085.
10. O'MALLEY, B.W., COPE, K.A., CHEN, S.H., LI, D., SCHWARTZ, M.R., and WOO, S.L. (1996). Combination gene therapy for oral cancer in a murine model. Cancer Res. 56, 1737-1741.
11. SELBY, S.M., ed. (1964). Standard Mathematical Tables, 15th Ed. (The Chemical Rubber Co., Cleveland, OH).
12. VOKES, E.E., WEICHSELBAUM, R.R., LIPPMAN, S.M., and HONG, W.K. (1993). Head and neck cancer. N. Engl. J. Med. 328, 184-191.
13. YAZAKI, T., MANZ, H.J., RABKIN, S.D., and MARTUZA, R.L. (1995). Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 55, 4752-4756.